Adaptive Biotechnologies entered 2026 as a story in transition: a commercial-stage immune-medicine company whose flagship clonoSEQ minimal residual disease (MRD) test had built real reimbursement traction, but whose second business - selling immune-receptor sequencing and target-discovery services to drugmakers - had lost its largest customer, Genentech, in 2025. The second quarter of fiscal 2026 delivered the answer to whether the profitable half of the company could carry the whole. Revenue rose 22% to $71.6 million, nearly all of it from MRD, which grew 33% to $66.2 million on 43% more clonoSEQ tests delivered. That growth is now translating into margin: the MRD segment turned Adjusted-EBITDA-positive at $9.1 million for the quarter, up from $1.9 million a year earlier, and - on TickerFile's allocation of the reported segment operating expenses - held just past a breakeven operating result for the second consecutive quarter.
The headline loss, however, was inflated by a one-time event. GAAP net loss widened to $39.9 million, but that included a $23.7 million loss on the early extinguishment of the company's OrbiMed revenue-interest liability - a debt-like obligation it retired in June. Strip that charge and the underlying net loss was roughly $16 million, modestly better than the year-ago $25.6 million and in line with the operating trajectory of a business approaching break-even on an adjusted basis (Adjusted EBITDA loss narrowed to $0.7 million from $7.2 million).
The quarter was defined by a capital-structure and portfolio reshuffle that reframes the investment case. Adaptive issued $345 million of zero-coupon convertible notes, paid off OrbiMed, repurchased stock, and announced its intention to separate the MRD and Immune Medicine businesses into independent units, with a preferred path identified by year-end. The thesis, in short: a cash-flowing MRD franchise about to be unburdened from a cash-burning research business, at a stock price more than double its 52-week low. The valuation now rests on whether the separation executes, whether clonoSEQ growth holds near the raised guidance of $268–278 million for the year, and whether MRD's new profitability is durable. The next records will read those clocks.